View live charts, options flow & technicals for IQVIA Holdings Inc. →
Open Dashboard
IQVIA Holdings Inc. (IQV) is a healthcare company in the diagnostics & research industry with $16.98B in trailing revenue trading at a 33.6× trailing P/E — analyst consensus: strong buy.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Key Statistics
Market Cap
$44.09B
Revenue (TTM)
$16.98B
EPS (TTM)
$7.98
EPS (Fwd est.)
$14.46
Employees
94,000
Trailing P/E
33.57
Forward P/E
18.52
PEG Ratio
0.98
Price / Sales
2.60
Price / Book
7.14
EV / EBITDA
19.16
Beta (5Y)
1.19
Analyst Consensus
Consensus
Strong Buy
Analyst Price Target
+3.8% upside
Target: $277.94
Annual Revenue & Net Income
RevenueNet Income
'22
$14.41B
$1.09B
'23
$14.98B
$1.36B
'24
$15.40B
$1.37B
'25
$16.31B
$1.36B
Earnings History
Quarter
Actual EPS
Estimate
Result
Jul 2026
$3.15
$3.03
Beat (+3.9%)
May 2026
$2.90
$2.82
Beat (+3.0%)
Feb 2026
$3.42
$3.40
Beat (+0.7%)
Oct 2025
$3.00
$2.98
Beat (+0.8%)
Next Earnings Report
IQVIA Holdings Inc. is next expected to report earnings on 03 Nov 2026.
Profitability
33.0%
13.0%
8.1%
Gross MarginOperating MarginNet Margin
Revenue Growth (YoY)
8.7%
Return on Equity
22.8%
Return on Assets
5.1%
Balance Sheet
Cash & Equivalents
$2.08B
Total Debt
$16.25B
Net Position
$14.17B (net debt)
Free Cash Flow (TTM)
$2.15B
Debt / Equity
257.98
Share Ownership
Institutions 103.4%
Insiders 1.1%
Institutional figure exceeds 100% due to short selling
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment off…
What is IQV's market cap?
IQVIA Holdings Inc. has a market capitalization of approximately $44.09B.
What is IQV's P/E ratio?
IQVIA Holdings Inc. trades at a trailing P/E ratio of 33.6x and a forward P/E of 18.5x, which is above the broad market average of ~25x.
How much revenue does IQV generate?
IQVIA Holdings Inc. generated $16.98B in trailing 12-month revenue.
What do analysts say about IQV?
The analyst consensus rating for IQVIA Holdings Inc. is strong buy, with a mean price target of $277.94. That implies +3.8% upside from the current price.
When does IQV report earnings?
IQVIA Holdings Inc. is next scheduled to report earnings on 03 Nov 2026.
Does IQV pay a dividend?
IQVIA Holdings Inc. does not currently pay a regular dividend.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for IQVIA Holdings Inc. on Apsis Markets.